Diasome Pharmaceuticals, Inc.

👥 13 employees💰 Last funded Jan 2020
Biotechnology🌐 diasome.com
Website LinkedIn
Diasome Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering hepatocyte cell drug targeting to restore hepatocyte metabolism and treat metabolic diseases. Diasomes Hepatocyte Targeting Platform reestablishes hepatocyte function, addressing the root cause of dysregulations central to major metabolic diseases such as diabetes, obesity, and dyslipidemia. Diasome aims to deliver superior patient outcomes and enhanced disease management by leveraging the hepatocytes natural regulatory functions.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Diasome Pharmaceuticals, Inc.?
Diasome Pharmaceuticals, Inc. has 2 investors on record on gritt.io.
When did Diasome Pharmaceuticals, Inc. last raise funding?
The most recent investment in Diasome Pharmaceuticals, Inc. recorded on gritt.io was in January 2020.
What industry is Diasome Pharmaceuticals, Inc. in?
Diasome Pharmaceuticals, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.